News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

biOasis Announces Transcend Vector Results With a Therapeutic Antibody That Targets Metastatic Breast Cancer



7/6/2011 10:16:51 AM

VANCOUVER, B.C., July 6, 2011 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) today announced results from two studies designed to assess the therapeutic potential of its Transcend vector in treating metastatic breast cancer. In these studies trastuzumab (tradename Herceptin), a humanized monoclonal antibody used clinically in the treatment of HER2-positive ("HER2+") breast cancer, was chemically linked to the Transcend delivery vector. The purpose of these studies was to assess if this conjugate can cross the blood-brain barrier and enter the tissue of the brain. And further, to test the effectiveness of the Transcend-trastuzumab conjugate (known as BT2111) against HER2+ cancer cells, verses trastuzumab on its own.

Read at GlobeNewswire


comments powered by Disqus
biOasis
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES